Gastric Cancer
Early Detection Test

About Us.

Ilico Genetics, a Spin Off of Pontificia Universidad Católica de Chile, is developing the first methylated DNA-based molecular test specifically designed for the early detection of gastric cancer, detecting cancer years before the industry gold standard, Upper Endoscopy (EGD).

With only a blood sample, our test detects a tumor in the stomach or lesions that could evolve into gastric cancer even without symptoms. The results are dynamic and show the cumulative presence of tumors over time.

Our test:

Reduces treatment costs by ~ 90%, compared to advanced stage treatments
Timely results to prioritize patients at risk (“fast track”)
Screening potential due to its low cost and ease of implementation
Monitoring capacity for the dynamic follow-up of premalignant lesions (i.e., gastric intestinal metaplasia or “GIM”)

Our Team

We are a multinational, intergenerational, and multidisciplinary team with proven experience in cancer research, laboratory operations, and business management. Our goal is to impact the lives of patients and their families by developing innovative genomic solutions.